Uncovering the genetic lesions underpinning cancer through genomic profiling in a clinical setting could provide insights into possible treatment options for oncologists and their patients. Next generation sequencing platforms are now paving the way to make numerous genomic and transcriptomic measurements including point mutations, copy number alterations, translocation mapping, and exon/allele specific transcriptome profiling with a single technology. We hope to apply this technology and build it out in a clinical setting to help oncologist determine the best course of treatment, currently for end-stage cancer patients. It is our hope that these technologies will be incorporated early in the clinical management of cancer to improve overall outcomes for patients.